IDegLira

DRUG10 trials

Sponsors

Emory University, Population Health Research Institute, Stefano Rizza, University of Campania Luigi Vanvitelli, Novo Nordisk A/S

Conditions

Diabetes MellitusDiabetes Mellitus, Type 2Type 2 DiabetesType 2 Diabetes MellitusType2 Diabetes

Phase 3

IDegLira HIGH Trial

CompletedNCT03737240

Emory UniversityDiabetes Mellitus

Start: 2019-01-15End: 2022-07-08Updated: 2023-09-08

Remission Evaluation of a Metabolic Intervention for Type 2 Diabetes With IDegLira

CompletedNCT03862716

Population Health Research InstituteType 2 Diabetes Mellitus

Start: 2019-04-23End: 2023-07-31Updated: 2023-10-25

Efficacy and Safety Of Different Regimens In Patients With Type 2 Diabetes Receiving Intensive Insulin Therapy

Xiangya Hospital of Central South UniversityType 2 Diabetes Mellitus

Start: 2022-09-01End: 2024-06-01Target: 78Updated: 2022-09-19

Phase 4

Durability of Combination of Insulin and GLP-1 Receptor Agonist or SGLT-2 Inhibitors Versus Basal Bolus Insulin Regimen in Type 2 Diabetes (BEYOND)

CompletedNCT04196231

University of Campania Luigi VanvitelliType 2 Diabetes

Start: 2019-11-27End: 2020-10-20Updated: 2020-10-22

The Efficacy and Safety of Insulin Degludec/Liraglutide Combination (IDegLira) in Patients With Type 2 Diabetes

Not yet recruitingNCT06408532

Peking University People's HospitalDiabetes Mellitus, Type 2

Start: 2024-04-30End: 2025-02-28Target: 256Updated: 2024-05-10

Unknown Phase

Quality of Life and Fixed-ratio Combination of Insulin Degludec and Liraglutide (iDegLira)

CompletedNCT04190160

Stefano RizzaType2 Diabetes

Start: 2018-11-19End: 2021-03-25Updated: 2021-08-03

GOAL: A Research Study Looking at Long Term Blood Sugar Control in People With Type 2 Diabetes Treated With Xultophy® in Local Clinical Practice in Japan.

CompletedNCT04838743

Novo Nordisk A/SDiabetes Mellitus, Type 2

Start: 2021-04-23End: 2022-10-26Updated: 2025-12-31

Glycaemic Control and Other Clinical Parameters in Adult Type 2 Diabetes Patients on Basal Insulin Initiating Treatment With IDegLira in Routine Clinical Practice in Colombia

CompletedNCT05324462

Novo Nordisk A/SDiabetes Mellitus, Type 2

Start: 2022-03-22End: 2022-07-15Updated: 2022-11-09

A Research Study Looking at Blood Sugar Control in People With Type 2 Diabetes Previously Treated With Premix Insulin and Initiating Treatment With Insulin Degludec/Liraglutide (IDegLira) in Local Clinical Practice in Croatia

WithdrawnNCT05479591

Novo Nordisk A/SDiabetes Mellitus, Type 2

Start: 2022-07-30End: 2023-04-30Updated: 2022-11-01

A Research Study in Italy to Understand How the Dose Check App Used With Xultophy® Works in the Treatment of People Living With Type 2 Diabetes

WithdrawnNCT06113341

Novo Nordisk A/SDiabetes Mellitus, Type 2

Start: 2024-11-07End: 2026-03-02Updated: 2024-10-01

Related Papers

SPIRIT: Assessing Clinical Parameters Associated with Using IDegLira in Patients with Type 2 Diabetes in a Real-World Setting in Colombia

Diabetes Therapy2024-05-082 citations

BEYOND 2 years: durability of metabolic benefits by simplification of complex insulin regimens in type 2 diabetes

Endocrine2023-10-038 citations